• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Prescribing Nirmatrelvir-Ritonavir: How to Recognize and Manage Drug-Drug Interactions.奈玛特韦利托那韦片的处方：如何识别和管理药物相互作用。
Ann Intern Med. 2022 May;175(5):744-746. doi: 10.7326/M22-0281. Epub 2022 Mar 1.
2
The interaction between nirmatrelvir/ritonavir and sirolimus: a case report of a kidney recipient with renal insufficiency and COVID-19.奈玛特韦/利托那韦与西罗莫司之间的相互作用：1例肾功能不全的肾移植受者合并新型冠状病毒肺炎的病例报告
J Int Med Res. 2025 Jan;53(1):3000605241307845. doi: 10.1177/03000605241307845.
3
Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system.奈玛特韦-利托那韦在预防 COVID-19 患者住院和死亡方面的有效性：美国大型医疗保健系统中的一项队列研究。
Lancet Infect Dis. 2023 Jul;23(7):806-815. doi: 10.1016/S1473-3099(23)00118-4. Epub 2023 Mar 15.
4
Prevalence of Potential Drug Interactions With Direct-Acting Antivirals for COVID-19 Among Hospitalized Patients.COVID-19 住院患者中直接作用抗病毒药物潜在药物相互作用的流行率。
Clin Ther. 2024 Oct;46(10):778-784. doi: 10.1016/j.clinthera.2024.08.004. Epub 2024 Sep 7.
5
The effect of nirmatrelvir-ritonavir on viral clearance and length of hospital stay in patients infected with SARS-CoV-2 omicron variants.奈玛特韦-利托那韦对感染 SARS-CoV-2 奥密克戎变异株患者的病毒清除和住院时间的影响。
Influenza Other Respir Viruses. 2023 Feb;17(2):e13095. doi: 10.1111/irv.13095.
6
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.奈玛特韦/利托那韦片用于 COVID-19 的预防和治疗。
Cochrane Database Syst Rev. 2023 Nov 30;11(11):CD015395. doi: 10.1002/14651858.CD015395.pub3.
7
Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study.美国科罗拉多州奥密克戎变异株（包括 BA.4 和 BA.5）流行期间门诊 COVID-19 患者使用奈玛特韦-利托那韦的真实世界数据：一项回顾性队列研究。
Lancet Infect Dis. 2023 Jun;23(6):696-705. doi: 10.1016/S1473-3099(23)00011-7. Epub 2023 Feb 10.
8
Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials - United States and International Sites, 2021-2022.2021 - 2022年在美国和国际多中心开展的随机、双盲、安慰剂对照试验中对奈玛特韦/利托那韦治疗后新型冠状病毒2（SARS-CoV-2）RNA反弹情况的评估
MMWR Morb Mortal Wkly Rep. 2023 Dec 22;72(51):1365-1370. doi: 10.15585/mmwr.mm7251a2.
9
Tacrolimus Drug-Drug Interaction with Nirmatrelvir/Ritonavir (Paxlovid™) Managed with Phenytoin.他克莫司与奈玛特韦/利托那韦（帕克洛维）的药物相互作用，并用苯妥英管理。
J Med Toxicol. 2023 Jan;19(1):45-48. doi: 10.1007/s13181-022-00922-2. Epub 2022 Dec 19.
10
Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19.莫努匹拉韦和奈玛特韦/利托那韦：新型可用的新冠病毒抗病毒药物选择
Acta Med Indones. 2022 Oct;54(4):638-644.

引用本文的文献

1
The Impact of COVID-19 and the Practical Importance of Vaccinations and Nirmatrelvir/Ritonavir for Patients with Cardiovascular Disease.新冠病毒病（COVID-19）的影响以及疫苗接种和奈玛特韦/利托那韦对心血管疾病患者的实际重要性
Vaccines (Basel). 2025 May 23;13(6):554. doi: 10.3390/vaccines13060554.
2
Patient Experiences With Nirmatrelvir/Ritonavir for COVID-19 in a Collaborative Care Model: A Cross-Sectional Study on Self-Management, Information, and Medication Impact.在协作护理模式下，患者使用奈玛特韦/利托那韦治疗 COVID-19 的体验：一项关于自我管理、信息及药物影响的横断面研究
J Patient Exp. 2025 May 14;12:23743735251342126. doi: 10.1177/23743735251342126. eCollection 2025.
3
Pharmacokinetic Interactions of Paxlovid Involving CYP3A Enzymes and P-gp Transporter: An Overview of Clinical Data.帕罗韦德与CYP3A酶和P-糖蛋白转运体的药代动力学相互作用：临床数据概述
Curr Drug Metab. 2024;25(9):639-652. doi: 10.2174/0113892002320326250123082112.
4
Paxlovid (Nirmatrelvir/Ritonavir)-Induced Tacrolimus Toxicity in Organ Transplant Recipients - A Review on Drug Interactions Involving CYP3A Enzymes.帕罗韦德（奈玛特韦/利托那韦）诱导器官移植受者发生他克莫司毒性——关于涉及CYP3A酶的药物相互作用的综述
Curr Drug Saf. 2025;20(3):291-302. doi: 10.2174/0115748863331165240821194206.
5
Cardiovascular Drug Interactions with Nirmatrelvir/Ritonavir for COVID-19: Considerations for Daily Practice.用于治疗新冠肺炎的心血管药物与奈玛特韦/利托那韦的相互作用：日常实践中的考量
Eur Cardiol. 2024 Aug 9;19:e15. doi: 10.15420/ecr.2024.04. eCollection 2024.
6
Abnormally Elevated Blood Tacrolimus Level Following the Concomitant Use of Nirmatrelvir/Ritonavir With Extended-Release Tacrolimus in a Post-lung Transplant Patient: A Case Report and a Literature Review.肺移植术后患者同时使用奈玛特韦/利托那韦与缓释他克莫司后血他克莫司水平异常升高：一例报告及文献综述
Cureus. 2024 Jun 21;16(6):e62868. doi: 10.7759/cureus.62868. eCollection 2024 Jun.
7
Ritonavir: 25 Years' Experience of Concomitant Medication Management. A Narrative Review.利托那韦：25年的联合用药管理经验。一篇叙述性综述。
Infect Dis Ther. 2024 May;13(5):1005-1017. doi: 10.1007/s40121-024-00959-6. Epub 2024 Apr 12.
8
Prevalence and Management of Medication Interactions with Nirmatrelvir-Ritonavir at a Large Urban Academic Medical Center: An Observational Study.大型城市学术医疗中心中与奈玛特韦-利托那韦药物相互作用的发生率及管理：一项观察性研究
J Gen Intern Med. 2024 Aug;39(10):1948-1950. doi: 10.1007/s11606-024-08750-6. Epub 2024 Apr 10.
9
Exploration of P1 and P4 modifications of nirmatrelvir: Design, synthesis, biological evaluation, and X-ray structural studies of SARS-CoV-2 Mpro inhibitors.探索奈玛特韦的 P1 和 P4 修饰：SARS-CoV-2 Mpro 抑制剂的设计、合成、生物学评价和 X 射线结构研究。
Eur J Med Chem. 2024 Mar 5;267:116132. doi: 10.1016/j.ejmech.2024.116132. Epub 2024 Feb 1.
10
Clinical course and management of COVID-19 in the era of widespread population immunity.广泛人群免疫时代下的 COVID-19 临床病程和管理。
Nat Rev Microbiol. 2024 Feb;22(2):75-88. doi: 10.1038/s41579-023-01001-1. Epub 2023 Dec 19.

奈玛特韦利托那韦片的处方：如何识别和管理药物相互作用。

Prescribing Nirmatrelvir-Ritonavir: How to Recognize and Manage Drug-Drug Interactions.

机构信息

Division of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and Clinical Research, University Hospital of Basel and University of Basel, Basel, Switzerland, and Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom (C.M.).

Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts (D.R.K.).

出版信息

Ann Intern Med. 2022 May;175(5):744-746. doi: 10.7326/M22-0281. Epub 2022 Mar 1.

DOI:10.7326/M22-0281
PMID:35226530
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8890619/
Abstract

Nirmatrelvir–ritonavir (NMV/r) is now being used to treat high-risk patients with mild to moderate COVID-19. This article provides advice to clinicians regarding recognition of medications likely to interact with NMV/r and suggests approaches to managing such drug–drug interactions. An algorithm is provided to assist in decision making.

摘要

尼马曲韦/利托那韦（NMV/r）现被用于治疗轻症至中症 COVID-19 的高危患者。本文为临床医生提供了有关识别可能与 NMV/r 相互作用的药物的建议，并提出了管理此类药物相互作用的方法。提供了一个算法来协助决策。